English

Polaris Group-KY announced that it has successfully completed its Year 2024 capital injection with fully raising NT$1,176 million and scheduling to list the newly issued shares on December 11, 2024. This successful capital injection received strong support from domestic and international investors, reflecting the market’s confidence in the company’s development prospects.

The breakthrough clinical trial of a rare and aggressive cancer treatment reveals: Polaris metabolic therapy drug, ADI-PEG 20, presents an innovative treatment approach that significantly enhances the survival rates of patients with malignant pleural mesothelioma (MPM), particularly demonstrating a fourfold increase in three-year survival rates compared to the placebo group.

TAIPEI, Taiwan and SAN DIEGO, Calif., Dec 21- Polaris Group (TWSE: 6550) announced that its board approved to increase the acquisition of Genovior Biotech’s shares to
100%. Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group. This significant decision not only allows
Polaris Group to expand the product pipeline beyond its novel cancer metabolism therapy but also marks its entry into the highly promising realm of peptide drugs, such as the widely recognized Semaglutide-related products. These two highly
prospective product lines will serve as the dual engines propelling Polaris Group’s future growth.

TAIPEI, Taiwan and SAN DIEGO, Calif., Nov 30 – Polaris Group (The Company, TWSE:6550), today announced that the first patient is successfully dosed in a pivotal Phase 3 trial that combines ADI-PEG 20 or placebo with traditional chemotherapy as systemic treatment in the second or third line for LMS.

TAIPEI, Taiwan and SAN DIEGO, Calif., November 29— Polaris Group (The Company, TWSE:6550), today announced that the first patient was successfully dosed in the Phase 2a clinical study for Non-Alcoholic Steatohepatitis (NASH).

TAIPEI, Taiwan and SAN DIEGO, Calif., Nov 17, 2023 – Polaris Group (The Company, TWSE:6550), today announced that the Company has initiated the rolling submission of its Biologic License Application (BLA) for ADI-PEG 20 to the U.S. Food and Drug Administration (FDA)for the systemic treatment of patients with malignant pleural mesothelioma with non-epithelioid histology, in combination with a platinum agent and pemetrexed. This submission is based on the results of the successful phase 3 trial of ADI-PEG 20 in combination with a platinum agent and pemetrexed which met both its primary and secondary objectives for progression free survival and overall survival. The rolling submission process allows for the submission of individual modules of the BLA as they are completed, which can streamline the regulatory review process and may expedite the potential approval timeline.

LARKSPUR, Calif.–(BUSINESS WIRE)–Global Coalition for Adaptive Research (LARKSPUR, CA) and Polaris Pharmaceuticals, Inc. (SAN DIEGO, CA), a subsidiary of Polaris Group (TWSE:6550)— The Global Coalition for Adaptive Research (GCAR) in collaboration with Polaris, today announced the activation of ADI-PEG 20 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447).

TAIPEI, Taiwan and SAN DIEGO, Calif., June 13, 2023 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, is proud to announce the appointment of Ken Chang, Ph.D., as Chief Strategy Officer and Hugh Yu, Ph.D., as Chief Operating Officer.

TAIPEI, Taiwan and VACAVILLE, Calif., June 07, 2023— Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, today announced that Polaris Group’s affiliate, Nanotein Technologies, has just launched GROW-NK, a novel Natural Killer (NK) cell activation and expansion reagent.

TAIPEI, Taiwan and SAN DIEGO, Calif., April 16, 2023 — Polaris Group (TWSE: 6550), a multinational biopharmaceutical company focused on research and development of novel biological drugs for cancer and other metabolic diseases, today presented data from its Phase 2/3 ATOMIC Study, a global, multi-center, randomized, double-blind, placebo-controlled trial of ADI-PEG 20 in combination with Pemetrexed and Cisplatin in patients with unresectable Malignant Pleural Mesothelioma (MPM) with biphasic or sarcomatoid histology.